A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease

Trial Profile

A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Osilodrostat (Primary)
  • Indications Pituitary ACTH hypersecretion
  • Focus Registrational; Therapeutic Use
  • Acronyms LINC-4
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Apr 2017 Trial design presented at The 99th Annual Meeting of the Endocrine Society
    • 03 Nov 2016 Planned End Date changed from 1 Jun 2018 to 1 Nov 2019.
    • 03 Nov 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top